Dengue

Also known as: dengue fever · dengue hemorrhagic fever

Definition

Dengue is a mosquito-borne viral infection spread mainly by the Aedes aegypti mosquito, with Aedes albopictus as a secondary vector, caused by the dengue virus — a flavivirus (formally Orthoflavivirus denguei) that circulates in four antigenically distinct serotypes, DENV-1 through DENV-4. Most infections are asymptomatic or mild, but a fraction progress to severe dengue, formerly known as dengue hemorrhagic fever, marked by plasma leakage, bleeding, and organ impairment; a second infection with a different serotype carries a greater risk of severe disease through antibody-dependent enhancement. The World Health Organization counts 100–400 million infections each year across more than 100 endemic countries, with reported cases rising from 505,430 in 2000 to 14.6 million in 2024. (WHO — Dengue and severe dengue, Wikipedia — Dengue fever, NCBI Taxonomy Browser)

The Philippines sits at the disease’s historic center: the severe hemorrhagic form of dengue was first reported in the Philippines in 1953, and by the 1970s the disease was a major cause of child mortality across Southeast Asia. The country has run a national dengue awareness month every June since 1998, and its surveillance record cycles between epidemic and lull years — most dramatically in 2019, when the Department of Health (DOH) declared a national dengue epidemic on August 6, 2019 after 146,062 cases and 622 deaths were recorded from January 1 to July 20 of that year. Philippine dengue policy also carries the burden of the Dengvaxia controversy, the world’s first mass dengue vaccination program suspended in 2017, which this site’s entries on the Department of Health (Philippines) and the Research Institute for Tropical Medicine frame from the institutional side. (Wikipedia — Dengue fever, Wikipedia — 2019–2020 dengue fever epidemic, Wikipedia — 2019 in the Philippines)

Identities

Source	Identifier	URL
Wikipedia	Dengue fever	https://en.wikipedia.org/wiki/Dengue_fever
Wikidata	Dengue fever (Q30953)	https://www.wikidata.org/wiki/Q30953
DBpedia	Dengue_fever	https://dbpedia.org/page/Dengue_fever
ProductOntology	Dengue fever	http://productontology.org/doc/Dengue_fever
Wiktionary	dengue	https://en.wiktionary.org/wiki/dengue
Library of Congress Subject Headings (LCSH)	Dengue (sh85036728)	https://id.loc.gov/authorities/subjects/sh85036728
MeSH	Dengue (D003715)	https://id.nlm.nih.gov/mesh/D003715
NCBI Taxonomy	Orthoflavivirus denguei (Dengue virus, taxid 12637)	https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=12637
AGROVOC	dengue (c_7b966257)	http://aims.fao.org/aos/agrovoc/c_7b966257
Google Scholar	dengue Philippines DENV-1 DENV-4 Aedes aegypti severe dengue DOH epidemic	https://scholar.google.com/scholar?q=dengue+Philippines+DENV+Aedes+aegypti+severe+dengue+DOH+epidemic
ConceptNet	dengue	http://conceptnet.io/c/en/dengue
OpenCyc	N/A	N/A

Also Known As

dengue fever
dengue hemorrhagic fever

Examples and Analogies

The four-serotype lottery: infection with one dengue serotype confers lifelong immunity to that type but only short-term protection against the others — and a subsequent infection with a different serotype raises the risk of severe disease through antibody-dependent enhancement, the immunological trap that also shaped the Dengvaxia warning. (Wikipedia — Dengue fever)
The day-biting city mosquito: the principal vector, Aedes aegypti, is an urban, day-feeding species that breeds in household water containers, so the battleground is the yard and the roof gutter rather than the swamp — which is why community clean-up campaigns anchor prevention in every endemic country. (WHO — Dengue and severe dengue, Wikipedia — Dengue fever)
The two-week clock: symptoms begin 4–10 days after the infective bite and last 2–7 days — high fever, severe headache, pain behind the eyes, muscle and joint pain, nausea, and rash — with the danger window opening when the fever falls and warning signs appear. (WHO — Dengue and severe dengue)
Verified data (virology, clinical, burden):
Serotypes: DENV-1 through DENV-4, the four child taxa of Orthoflavivirus denguei (taxid 12637) in the NCBI Taxonomy (NCBI Taxonomy Browser, Wikipedia — Dengue fever)
Global burden: 100–400 million infections yearly; reported cases up from 505,430 (2000) to 14.6 million (2024), with more than 12,000 deaths in 2024 (WHO — Dengue and severe dengue)
Severe-dengue risk: roughly 5 percent of symptomatic cases are severe; case fatality is below 1 percent with adequate treatment but can reach 26 percent when blood pressure falls very low (Wikipedia — Dengue fever)
Philippines 2019: 146,062 cases and 622 deaths from January 1 to July 20 — a 98 percent increase over the same period in 2018; year-end totals of 420,453 cases and 1,565 deaths, second only to Brazil (Wikipedia — 2019–2020 dengue fever epidemic)
Philippines 2020: 60,819 cases and 236 deaths in the pandemic-year lull (Wikipedia — 2019–2020 dengue fever epidemic)

Usage Scenarios

1. Clinical Recognition and Triage

Frontline clinicians classify suspected dengue by phase — febrile, critical, recovery — and watch for the WHO warning signs that demand immediate care: severe abdominal pain, persistent vomiting, rapid breathing, bleeding gums or nose, blood in vomit or stool, extreme thirst, and pale, cold skin, often appearing after the fever subsides. Management is supportive: paracetamol for pain, intravenous fluids and transfusion in severe cases, and no aspirin, ibuprofen, or naproxen because of bleeding risk. (WHO — Dengue and severe dengue, Wikipedia — Dengue fever)

2. Surveillance and Epidemic Declaration

The Philippine pattern is escalation by declaration: Health Secretary Francisco Duque III declared a National Dengue Alert on July 15, 2019 as cases climbed across the regions, and the DOH declared the national dengue epidemic on August 6, 2019 after the epidemiology bureau’s count passed 146,000 cases with 622 deaths — the formal trigger for a coordinated national response under the country’s notifiable-disease reporting system, which this site’s Republic Act 11332 entry documents. (Wikipedia — 2019 in the Philippines, Wikipedia — 2019–2020 dengue fever epidemic)

3. Vaccination Policy

The Philippines was the first Asian country to approve Dengvaxia (December 2015) and launched the world’s first school-based dengue vaccination drive in April 2016; after Sanofi’s November 29, 2017 disclosure that the vaccine could harm recipients without prior dengue infection, the program was suspended, and vaccine policy worldwide shifted to serostatus screening. Globally the licensed successor is Qdenga (TAK-003), recommended by WHO in 2023 for children 6–16 in high-transmission settings, and the DOH has expanded a dengue vaccination pilot to major urban centers in 2025 and 2026. (Wikipedia — Dengvaxia controversy, Wikipedia — Dengue vaccine, Wikipedia — Dengue fever)

4. Vector Control and Public Campaigns

Because there is no specific antiviral, prevention rests on mosquito control — destroying breeding sites in stored water, personal protection against daytime bites, and community clean-up drives — delivered in the Philippines through the June dengue awareness month observed since 1998 and the barangay health networks this site’s entries on the barangay health worker and the Department of Health (Philippines) describe. (Wikipedia — Dengue fever, WHO — Dengue and severe dengue)

Strategies

Treat the warning signs, not just the fever: the WHO protocol ties hospital referral to the post-fever danger window — abdominal pain, persistent vomiting, bleeding, restlessness — because severe dengue is a medical emergency that unfolds after temperature normalizes. (WHO — Dengue and severe dengue)
Screen before vaccinating: the Dengvaxia lesson institutionalized pre-vaccination serological testing — the 2018 WHO position restricts the first-generation vaccine to previously infected recipients — and shapes how second-generation vaccines are introduced. (Wikipedia — Dengue vaccine, Wikipedia — Dengvaxia controversy)
Use the surveillance ladder: the Philippine sequence of 2019 — dengue alert in July, national epidemic in August — shows declarations ratcheting with case counts, converting routine reporting into resource mobilization. (Wikipedia — 2019 in the Philippines)
Fight the mosquito at the water container: vector control targets the urban Aedes breeding economy of tires, tanks, and gutters rather than adult spraying alone, the approach shared by WHO and Philippine guidance. (WHO — Dengue and severe dengue, Wikipedia — Dengue fever)
Expect the cycle: Philippine dengue arrives in multi-year waves — 119,789 cases in 2010, epidemic in 2019, lull in 2020, renewed provincial outbreaks by 2024–2025 — so planning is cyclical, not one-off. (Wikipedia — Dengue fever outbreaks, Wikipedia — 2019–2020 dengue fever epidemic)

Security and Safety Measures

Know the warning signs and act immediately: severe abdominal pain, persistent vomiting, rapid breathing, bleeding gums or nose, blood in vomit or stool, extreme thirst, and pale cold skin require urgent hospital care — the single most important household safety rule in dengue. (WHO — Dengue and severe dengue)
Avoid NSAIDs during febrile illness: aspirin, ibuprofen, and naproxen increase bleeding risk in dengue; paracetamol is the safe analgesic. (WHO — Dengue and severe dengue)
Protect against daytime bites: because Aedes aegypti feeds by day in and around homes, personal protection and screening of water storage deny the vector both blood meals and breeding sites. (WHO — Dengue and severe dengue, Wikipedia — Dengue fever)
Verify serostatus before first-generation vaccination: Dengvaxia is restricted to laboratory-confirmed previously infected recipients, the regulatory safeguard that emerged from the Philippine program. (Wikipedia — Dengue vaccine)
Sustain surveillance between epidemics: the 2019 declaration rested on weekly case reporting that showed a 98 percent jump over 2018 — capacity that must be maintained in quiet years to catch the next wave. (Wikipedia — 2019–2020 dengue fever epidemic)

Historical Context

Dengue’s modern identity was forged in the Philippines and Southeast Asia. The severe hemorrhagic form was first reported in the Philippines in 1953, and by the 1970s it ranked among the leading causes of child mortality in the region; the Philippine epidemic record since then runs in waves — 119,789 cases and 724 deaths in 2010, roughly 42,500 cases with about 200 deaths by mid-2013, and the great epidemic of 2019, when the DOH’s August 6 national declaration followed a July 15 dengue alert and closed the year at 420,453 cases and 1,565 deaths, second worldwide only to Brazil. The epidemic year of 2020 fell to 60,819 cases, and provincial resurgences returned by the mid-2020s, Iloilo alone recording 2,927 cases by late July 2025 against its 2024 total of 2,424. (Wikipedia — Dengue fever, Wikipedia — Dengue fever outbreaks, Wikipedia — 2019–2020 dengue fever epidemic, Wikipedia — 2019 in the Philippines)

The second historical thread is vaccination. The Philippines approved Dengvaxia in December 2015 as the first Asian country to do so, launched the school-based program in April 2016 with about ₱3.5 billion for more than 733,000 children, and suspended it after Sanofi’s November 29, 2017 announcement of risk to seronegative recipients; a February 2018 UP–Philippine General Hospital review of deaths among vaccinees fed a public reckoning that also depressed confidence in other vaccines, including measles immunization. The episode redrew global dengue vaccine policy — WHO’s 2018 screening requirement, and the 2022–2023 licensure and WHO recommendation of Qdenga — even as the DOH returned to vaccination cautiously, expanding an urban pilot program in 2025 and 2026. (Wikipedia — Dengvaxia controversy, Wikipedia — Dengue vaccine, Wikipedia — Dengue fever)

Challenges and Controversies

The Dengvaxia Controversy

The documented record: the Philippines ran the world’s first mass dengue vaccination program from April 2016, Sanofi disclosed on November 29, 2017 that Dengvaxia risked severe disease in previously uninfected recipients, the DOH suspended the program and the product was later barred, and investigations followed — including the UP-PGH finding that of 14 vaccinated children who died, three showed dengue despite immunization. The controversy’s shadow on Philippine public health, from parental vaccine hesitancy to the political aftermath of 2019’s epidemic, remains the central policy controversy of Philippine dengue control. (Wikipedia — Dengvaxia controversy)

The Cyclical Epidemic Burden

The 2019 epidemic — 420,453 cases and 1,565 deaths, the world’s second-largest national burden that year — exemplifies the unresolved challenge of a disease whose curve swings between lull and crisis: 2020’s 60,819 cases gave way to renewed provincial outbreaks in 2024–2025, with Quezon City declaring an outbreak in February 2025 and Iloilo’s cases exceeding its 2024 total by late July 2025. (Wikipedia — 2019–2020 dengue fever epidemic, Wikipedia — Dengue fever outbreaks)

Vaccination Policy After Dengvaxia

Whether and how to reintroduce dengue vaccination is contested ground: Dengvaxia is restricted to the previously infected, Qdenga — licensed in Indonesia and the EU from 2022 and WHO-recommended in 2023 — is not part of a documented national Philippine program, and the DOH’s 2025–2026 pilot expansion proceeds cautiously in the country where the first mass program ended. (Wikipedia — Dengue vaccine, Wikipedia — Dengue fever)

Counting and Declaring

The epidemic declaration machinery itself is debated: the 2019 sequence shows a national alert on July 15 and an epidemic declaration on August 6, by which point 622 deaths had already accrued — critics ask whether earlier declaration would have blunted a year that ended with 1,565 deaths, a question the case counts of subsequent years keep alive. (Wikipedia — 2019 in the Philippines, Wikipedia — 2019–2020 dengue fever epidemic)